Something remarkable has happened in the Indian pharmaceutical market. Mounjaro, Eli Lilly’s tirzepatide, is now India's No. 1 pharmaceutical brand by monthly value, according to Pharmarack’s July 2026 Pharma Monitor. At approximately Rs 109.8 crore for July, Mounjaro has overtaken some of the most deeply entrenched brands in Indian medicine, including Augmentin, Glycomet GP, Zerodol SP, PAN, Foracort, Udiliv, and Thyronorm. It recorded 157 per cent growth and an incremental gain of approximately Rs 67 crore.
The rise is even more striking at the corporate level. Eli Lilly ranked only 35th among pharmaceutical companies in India in July, with sales of approximately Rs 117 crore. Yet the company grew 92 per cent, with Pharmarack explicitly identifying tirzepatide as the principal driver.
Free Membership Required
You must be a Free member to access this content.
